[go: up one dir, main page]

FI20090161A0 - Uusi solu ja siihen pohjautuvia terapeuttisia ja diagnostisia menetelmiä - Google Patents

Uusi solu ja siihen pohjautuvia terapeuttisia ja diagnostisia menetelmiä

Info

Publication number
FI20090161A0
FI20090161A0 FI20090161A FI20090161A FI20090161A0 FI 20090161 A0 FI20090161 A0 FI 20090161A0 FI 20090161 A FI20090161 A FI 20090161A FI 20090161 A FI20090161 A FI 20090161A FI 20090161 A0 FI20090161 A0 FI 20090161A0
Authority
FI
Finland
Prior art keywords
therapeutical
methods based
diagnostic methods
new cell
diagnostic
Prior art date
Application number
FI20090161A
Other languages
English (en)
Swedish (sv)
Inventor
Sirpa Jalkanen
Marko Salmi
Markku Jalkanen
Original Assignee
Faron Pharmaceuticals Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Faron Pharmaceuticals Oy filed Critical Faron Pharmaceuticals Oy
Priority to FI20090161A priority Critical patent/FI20090161A0/fi
Publication of FI20090161A0 publication Critical patent/FI20090161A0/fi
Priority to ES10766694.3T priority patent/ES2666185T3/es
Priority to PCT/FI2010/050266 priority patent/WO2010122217A1/en
Priority to CA3022659A priority patent/CA3022659C/en
Priority to DK10766694.3T priority patent/DK2421888T3/en
Priority to PL10766694T priority patent/PL2421888T3/pl
Priority to HRP20180580TT priority patent/HRP20180580T1/hr
Priority to HUE10766694A priority patent/HUE037394T2/hu
Priority to NO10766694A priority patent/NO2421888T3/no
Priority to US13/262,088 priority patent/US8722045B2/en
Priority to SM20180211T priority patent/SMT201800211T1/it
Priority to LTEP10766694.3T priority patent/LT2421888T/lt
Priority to EP17197919.8A priority patent/EP3330281A1/en
Priority to SI201031666T priority patent/SI2421888T1/en
Priority to CA2757706A priority patent/CA2757706C/en
Priority to EP10766694.3A priority patent/EP2421888B1/en
Priority to JP2012506538A priority patent/JP5819285B2/ja
Priority to PT107666943T priority patent/PT2421888T/pt
Priority to US14/224,374 priority patent/US10526607B2/en
Priority to JP2015150694A priority patent/JP6141919B2/ja
Priority to CY20181100423T priority patent/CY1120175T1/el
Priority to HK18115414.6A priority patent/HK1256330A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/202—IL-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
FI20090161A 2009-04-22 2009-04-22 Uusi solu ja siihen pohjautuvia terapeuttisia ja diagnostisia menetelmiä FI20090161A0 (fi)

Priority Applications (22)

Application Number Priority Date Filing Date Title
FI20090161A FI20090161A0 (fi) 2009-04-22 2009-04-22 Uusi solu ja siihen pohjautuvia terapeuttisia ja diagnostisia menetelmiä
PT107666943T PT2421888T (pt) 2009-04-22 2010-04-06 Antagonistas do recetor clever-1 para bloqueamento de macrófagos de tipo 2 imunoinibidores
SM20180211T SMT201800211T1 (it) 2009-04-22 2010-04-06 Antagonisti del recettore clever-1 per bloccare i macrofagi immuno-inibitori di tipo 2
EP17197919.8A EP3330281A1 (en) 2009-04-22 2010-04-06 Clever-1 levels as marker for increased anti-tumor response
CA3022659A CA3022659C (en) 2009-04-22 2010-04-06 A novel cell and therapeutical and diagnostical methods based thereon
DK10766694.3T DK2421888T3 (en) 2009-04-22 2010-04-06 CLEVER-1 receptor antagonists to block immune-inhibitory type 2 macrophages
PL10766694T PL2421888T3 (pl) 2009-04-22 2010-04-06 Antagoniści receptora clever-1 do blokowania makrofagów typu 2 hamujących układ immunologiczny
HRP20180580TT HRP20180580T1 (hr) 2009-04-22 2010-04-06 Antagonisti receptora clever-1, namijenjeni blokiranju makrofaga imunoinhibicijskog tipa 2
HUE10766694A HUE037394T2 (hu) 2009-04-22 2010-04-06 Clever-1 receptor antagonisták immun-gátló 2 típusú makrofágok blokkolására
NO10766694A NO2421888T3 (fi) 2009-04-22 2010-04-06
US13/262,088 US8722045B2 (en) 2009-04-22 2010-04-06 Cell and therapeutical and diagnostical methods based thereon
ES10766694.3T ES2666185T3 (es) 2009-04-22 2010-04-06 Antagonistas del receptor CLEVER-1 para bloquear los macrófagos inmuno-inhibidores de tipo 2
LTEP10766694.3T LT2421888T (lt) 2009-04-22 2010-04-06 Clever-1 receptorių antagonistai, skirti blokuoti imunitetą slopinančius 2 tipo makrofagus
PCT/FI2010/050266 WO2010122217A1 (en) 2009-04-22 2010-04-06 A novel cell and therapeutical and diagnostical methods based thereon
SI201031666T SI2421888T1 (en) 2009-04-22 2010-04-06 CLEVER-1 receptor antagonists for blocking immunomodulatory macrophages of type 2.
CA2757706A CA2757706C (en) 2009-04-22 2010-04-06 A novel cell and therapeutical and diagnostical methods based thereon
EP10766694.3A EP2421888B1 (en) 2009-04-22 2010-04-06 CLEVER-1 Receptor Antagonists for blocking immune-inhibitory type 2 macrophages.
JP2012506538A JP5819285B2 (ja) 2009-04-22 2010-04-06 子癇前症の検出を補助する方法またはそのリスクの推定を補助する方法
US14/224,374 US10526607B2 (en) 2009-04-22 2014-03-25 Cell and therapeutical and diagnostical methods based thereon
JP2015150694A JP6141919B2 (ja) 2009-04-22 2015-07-30 新規細胞上のＣｌｅｖｅｒ−１をモジュレートし得る医薬組成物
CY20181100423T CY1120175T1 (el) 2009-04-22 2018-04-23 Ανταγωνιστες υποδοχεα clever-1 για αποκλεισμο των ανοσο-ανασταλτικων μακροφαγων τυπου 2
HK18115414.6A HK1256330A1 (en) 2009-04-22 2018-12-03 Clever-1 levels as marker for increased anti-tumor response

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI20090161A FI20090161A0 (fi) 2009-04-22 2009-04-22 Uusi solu ja siihen pohjautuvia terapeuttisia ja diagnostisia menetelmiä

Publications (1)

Publication Number Publication Date
FI20090161A0 true FI20090161A0 (fi) 2009-04-22

Family

ID=40590220

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20090161A FI20090161A0 (fi) 2009-04-22 2009-04-22 Uusi solu ja siihen pohjautuvia terapeuttisia ja diagnostisia menetelmiä

Country Status (18)

Country Link
US (2) US8722045B2 (fi)
EP (2) EP2421888B1 (fi)
JP (2) JP5819285B2 (fi)
CA (2) CA2757706C (fi)
CY (1) CY1120175T1 (fi)
DK (1) DK2421888T3 (fi)
ES (1) ES2666185T3 (fi)
FI (1) FI20090161A0 (fi)
HK (1) HK1256330A1 (fi)
HR (1) HRP20180580T1 (fi)
HU (1) HUE037394T2 (fi)
LT (1) LT2421888T (fi)
NO (1) NO2421888T3 (fi)
PL (1) PL2421888T3 (fi)
PT (1) PT2421888T (fi)
SI (1) SI2421888T1 (fi)
SM (1) SMT201800211T1 (fi)
WO (1) WO2010122217A1 (fi)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109311983B (zh) * 2016-04-18 2022-05-17 法龙药品公司 人源化抗clever-1抗体及其用途
CA3020418A1 (en) * 2016-04-18 2017-10-26 Faron Pharmaceuticals Oy Diagnosis of immune_activation using clever-1, tnf-alpha and hla-dr binding agents
CA3113895A1 (en) 2018-11-01 2020-05-07 Faron Pharmaceuticals Oy Tlr9 agonists for use in downregulating clever-1 expression on alternatively activated macrophages
GB201903015D0 (en) * 2019-03-08 2019-04-17 Univ Edinburgh Macrophage expression in breast cancer
PL4034885T3 (pl) * 2019-09-24 2025-01-07 Faron Pharmaceuticals Oy Sposób określania siły działania terapeutycznego przeciwciała anty-clever-1
WO2021100891A1 (ko) * 2019-11-19 2021-05-27 경상대학교병원 구강암 예후 진단용 조성물 및 키트
FI129383B (fi) 2020-06-15 2022-01-31 Faron Pharmaceuticals Oy Stabiili anti-clever-1 -vasta-aineformulaatio
US20220227858A1 (en) 2021-01-18 2022-07-21 Faron Pharmaceuticals Oy Controlling of immune activation by soluble clever-1
EP4423507A1 (en) * 2021-12-07 2024-09-04 Faron Pharmaceuticals OY Method for using inflammatory markers to guide anti-clever-1 cancer treatment
WO2023222953A1 (en) * 2022-05-20 2023-11-23 Faron Pharmaceuticals Oy Method for identifying cancer patients that benefit from anti-clever-1 treatment
JP2025516877A (ja) * 2022-05-20 2025-05-30 ファロン ファーマシューティカルズ オサケ ユキチュア 抗ｃｌｅｖｅｒ－１治療の恩恵を受けるがん患者を同定する方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
AU3395900A (en) * 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
US7279294B2 (en) * 2000-04-03 2007-10-09 The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services, Nih Tumor markers in ovarian cancer
US20030190635A1 (en) 2002-02-20 2003-10-09 Mcswiggen James A. RNA interference mediated treatment of Alzheimer's disease using short interfering RNA
EP1386004A4 (en) 2001-04-05 2005-02-16 Ribozyme Pharm Inc MODULATION OF GENE EXPRESSION ASSOCIATED WITH INFLAMMATORY PROLIFERATION AND GROWTH OF NEURITIES BY METHODS INVOLVING NUCLEIC ACID
US20030175950A1 (en) 2001-05-29 2003-09-18 Mcswiggen James A. RNA interference mediated inhibition of HIV gene expression using short interfering RNA
US20040019001A1 (en) 2002-02-20 2004-01-29 Mcswiggen James A. RNA interference mediated inhibition of protein typrosine phosphatase-1B (PTP-1B) gene expression using short interfering RNA
EP1463760B1 (en) * 2002-01-09 2007-09-05 Faron Pharmaceuticals OY Common lymphatic endothelial and vascular endothelial receptor-1 (clever-1) and uses thereof
WO2004028471A2 (en) 2002-09-28 2004-04-08 Massachusetts Institute Of Technology Influenza therapeutic
US20040191783A1 (en) * 2003-03-31 2004-09-30 Guy Leclercq Low density micro-array analysis in human breast cancer
US20050043266A1 (en) 2003-07-25 2005-02-24 Sumedha Jayasena Short interfering RNA as an antiviral agent for hepatitis C
EP1661915A1 (en) * 2004-11-25 2006-05-31 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Preparation of antibodies against the human chitinase-like protein GL008
FI20050640A0 (fi) 2005-06-16 2005-06-16 Faron Pharmaceuticals Oy Yhdisteitä amiinioksidaasista riippuvien sairauksien tai häiriöiden hoitoon tai estoon
EP1889922A1 (en) 2006-08-18 2008-02-20 Burdach, Stefan Methods for diagnosis of pediatric common acute lymphoblastic leukemia by determining the level of gene expression
US20110119776A1 (en) * 2007-02-05 2011-05-19 Wong Kwok-Kin Methods of diagnosing and prognosing lung cancer
US10359425B2 (en) * 2008-09-09 2019-07-23 Somalogic, Inc. Lung cancer biomarkers and uses thereof

Also Published As

Publication number Publication date
DK2421888T3 (en) 2018-05-22
CA2757706C (en) 2019-01-15
US20120027770A1 (en) 2012-02-02
WO2010122217A1 (en) 2010-10-28
CY1120175T1 (el) 2018-12-12
EP2421888B1 (en) 2018-02-21
JP5819285B2 (ja) 2015-11-24
HRP20180580T1 (hr) 2018-06-29
EP2421888A1 (en) 2012-02-29
JP6141919B2 (ja) 2017-06-07
SI2421888T1 (en) 2018-06-29
LT2421888T (lt) 2018-05-25
EP3330281A1 (en) 2018-06-06
JP2012524536A (ja) 2012-10-18
JP2016020351A (ja) 2016-02-04
NO2421888T3 (fi) 2018-07-21
ES2666185T3 (es) 2018-05-03
US10526607B2 (en) 2020-01-07
US20140294760A1 (en) 2014-10-02
PL2421888T3 (pl) 2018-07-31
HK1256330A1 (en) 2019-09-20
HUE037394T2 (hu) 2018-08-28
SMT201800211T1 (it) 2018-05-02
CA3022659A1 (en) 2010-10-28
PT2421888T (pt) 2018-05-09
EP2421888A4 (en) 2013-03-06
CA3022659C (en) 2021-04-06
US8722045B2 (en) 2014-05-13
CA2757706A1 (en) 2010-10-28

Similar Documents

Publication Publication Date Title
FI20090161A0 (fi) Uusi solu ja siihen pohjautuvia terapeuttisia ja diagnostisia menetelmiä
IL254144A0 (en) Methods for reprogramming cells and uses thereof
BR112012025762A2 (pt) dispositivo de injeção de eletrólito e método de injeção de eletrólito
BRPI1014404A2 (pt) cânula dotada de recurso de cânula e recurso de encaixe em sobreposição
BRPI0910259A2 (pt) métodos de tratamento de inflamação
EP2296593A4 (en) MEDICAL HEAD COVER
BR112013009489A2 (pt) aparelho e método de conexão
BR112013013584A2 (pt) endoscópio, e, método
BRPI1013655A8 (pt) dispositivo e método cirúrgico
PL2294582T3 (pl) Urządzenie i sposób wytwarzania izotopów medycznych
BR112012011910A2 (pt) dispositivo e método
DK3718922T3 (da) Glucoseovervågningssystem og fremgangsmåde
DK2427107T3 (da) Elektrodefikseringsindretning
EP2391971A4 (en) NON-INVASIVE DIAGNOSTIC SYSTEM
EP2351511A4 (en) MEDICAL DEVICE OF CAPSULE TYPE
EP2424614A4 (en) INTEGRATED ELECTRODE CONNECTOR AND IMPEDANCE INDICATOR
EP2404992A4 (en) SYSTEM FOR EVALUATING CELLS USING A CELLULAR SHEET AND METHOD OF USING THE SAME
BR112012014996A2 (pt) método diagnóstico baseado em reaaranjo somaticamente adquirido
BRPI0915822A2 (pt) dispositivo médico
EP2407789A4 (en) ANALYTICAL DEVICE
BRPI1007909A2 (pt) método e dispositivo médico
EP2578153A4 (en) AUDIO METERS AND METHOD THEREFOR
EP2471475A4 (en) CANNULA AND METHOD FOR PRODUCING THE SAME
EP2440937A4 (en) A diagnostic method
FI20090357L (fi) Menetelmä ja järjestely

Legal Events

Date Code Title Description
FD Application lapsed